SECUKINUMAB IMPROVES MINIMAL DISEASE ACTIVITY RESPONSE RATES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE RANDOMIZED PHASE 3 STUDY, FUTURE 2

被引：4

作者：

Coates, L. C. ^{[1
,2
]}

Mease, P. ^{[3
]}

Kirkham, B. ^{[4
]}

McLeod, L. D. ^{[5
]}

Mpofu, S. ^{[6
]}

Karyekar, C. ^{[7
]}

Gandhi, K. ^{[7
]}

机构：

[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[2] Leeds Teaching Hosp NHS Trust, Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England

[3] Univ Washington, Seattle, WA 98195 USA

[4] Guys & St Thomas NHS Fdn Trust, London, England

[5] RTI Hlth Solut, Res Triangle Pk, NC USA

[6] Novartis Pharma AG, Basel, Switzerland

[7] Novartis Pharmaceut, E Hanover, NJ USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷

关键词：

D O I：

10.1136/annrheumdis-2016-eular.3949

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0463

引用

页码：605 / 605

页数：1

共 50 条

[1] SECUKINUMAB IMPROVES MINIMAL DISEASE ACTIVITY RESPONSE RATES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM PHASE 3 FUTURE-2 STUDY
Mease, P.
Coates, L. C.
Kirkham, B.
McLeod, L. D.
Mpofu, S.
Karyekar, C.
Gandhi, K.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 777 - 778
[2] SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 STUDY, FUTURE 5
Mease, Philip J.
van der Heijde, D.
Landewe, R.
Mpofu, S.
Rahman, P.
Tahir, H.
Singhal, A.
Navarra, S.
Boettcher, E.
Zhu, X.
Readie, A.
Pricop, L.
Abrams, K.
ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 17 - 18
[3] Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Coates, Laura
Mease, Philip
Gladman, Dafna
Navarra, Sandra
Bao, Weibin
Gaillez, Corine
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[4] Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study
Kirkham, B.
Nash, P.
Reina, D.
Navarra, S.
Quebe-Fehling, E.
Gaillez, C.
Sastre, C.
Mease, P. J.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (03) : 589 - 596
[5] SECUKINUMAB IMPROVES PHYSICAL FUNCTION, QUALITY OF LIFE, FATIGUE AND WORK PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN FUTURE 2, A PHASE 3 TRIAL
Rahman, P.
Strand, V.
McInnes, I. B.
Marzo-Ortega, H.
Dokoupilova, E.
Churchill, M.
Kandala, S.
Pricop, L.
Mpofu, S.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 356 - 356
[6] SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS BURDEN IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PHASE 3 FUTURE 2 STUDY
Gottlieb, A.
McInnes, I. B.
Mease, P.
Rahman, P.
Kandala, S.
Patekar, M.
Mpofu, S.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 349 - 350
[7] SECUKINUMAB SAFETY AND TOLERABILITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED SAFETY ANALYSIS OF TWO PHASE 3, RANDOMIZED, CONTROLLED TRIALS (FUTURE 1 AND FUTURE 2)
Mease, P.
McInnes, I. B.
Richards, H.
Pricop, L.
Widmer, A.
Mpofu, S.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 870 - 871
[8] IMPACT OF SECUKINUMAB TREATMENT ON PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE: POOLED DATA FROM FUTURE 2 AND FUTURE 3 PHASE 3 STUDIES
McInnes, Iain B.
Wallman, Johan K.
Schett, Georg
Quebe-Fehling, Erhard
Rasouliyan, Lawrence
Pricop, Luminita
Fasth, Andreas E.
Gaillez, Corine
RHEUMATOLOGY, 2019, 58
[9] Secukinumab improves signs and symptoms of psoriatic arthritis: Results of phase 3 FUTURE 2 study stratified by concomitant methotrexate use
Gottlieb, Alice B.
McInnes, Iain
Mease, Philip
Mpofu, Shephard
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB270 - AB270
[10] SECUKINUMAB PROVIDES SUSTAINED MINIMAL DISEASE ACTIVITY (MDA) AND REMISSION RELATED TO DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS (DAPSA): 2-YEAR RESULTS FROM A PHASE 3 STUDY
Coates, Laura C.
Nash, Peter
Kvien, Tore Kristian
Gossec, Laure
Mease, Philip J.
Rasouliyan, Lawrence
Pricop, Luminita
Gaillez, Corine
Smolen, Josef S.
ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 21 - 22

← 1 2 3 4 5 →